Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer

Inclusion Criteria: * Histologically confirmed metastatic squamous or non-squamous non-small cell lung cancer. * Previously treated with at least one line of therapy including an immune checkpoint blocker and no more than 2 prior lines in the metastatic setting. * Documented PD-L1 expression of at least 1% by a US FDA-approved PD-L1 assay or using the clone 22C3 antibody from archival biopsy or fresh tumor tissue. * At least one measurable lesion per RECIST 1.1 criteria. * At least 18 years of age. * ECOG performance status ≤ 1. * Normal bone marrow and organ function as defined below: * Absolute neutrophil count ≥ 1,500/µL * Platelets ≥ 100,000/µL * Hemoglobin ≥ 9.0 g/dL * Total bilirubin ≤ 2.0 x IULN (except participants with Gilbert's syndrome who must have total bilirubin \< 3.0 mg/dL) * AST(SGOT)/ALT(SGPT) ≤ 2.5 x IULN without hepatic metastasis and ≤ 5.0 x IULN with hepatic metastasis * Creatinine ≤2 x ULN or Creatinine clearance calculated by Cockcroft-Gault formula ≥45 ml/min * Patients with brain or meningeal metastases are eligible provided they meet the following criteria: * No evidence of progression by neurologic symptoms or signs for at least 4 weeks prior to first dose of study treatment * Metastatic brain lesions that do not require immediate intervention * No use of corticosteroids with dose above 10 mg prednisone (or equivalent) * The effects of the study drugs on the developing human fetus are unknown. For this reason, women of childbea…